Alzheimer's Disease (AD)
An estimated 4.5 million Americans are living with Alzheimer's disease (AD) today, and that number is projected to more than triple by 2050. Alzheimer's disease is the most common form of disabling memory and thinking problems in older people. In its most severe stage, afflicted individuals may be extremely confused and even unable to swallow food. In addition to its effect on patients, the disease often takes an overwhelming toll on family caregivers.
TGen's Alzheimer's research project uses state-of-the-art techniques that are able to pin point single cell differences or "gene expressions" in which allows the researchers to identify novel or unique genes and pathways that contribute to the development and progression of this tragic disorder.
TGen, in conjunction with other leaders in Alzheimer's genetics research, like the Arizona Alzheimer's Disease Consortium, has undertaken a large collaborative effort to identify every genetic variation that results in increased risk for Alzheimer's disease. By scanning the genome of thousands of individuals both with and without the disease, TGen hopes to identify the genetic differences or variants that contribute a significant increased risk for developing the disease. These genetic variants can be used to provide new information about the causes of Alzheimer's and as a diagnostic tool to determine an individual's inherent genetic risk for the disorder.
TGen's Neurodegenerative Research Unit
Dr. Eric Reiman
Your donation in support of Alzheimer's research at TGen is important to furthering the institute's mission to develop earlier diagnoses and smarter treatments for patients.
Volunteer! Become a TGen Ambassador and help raise funds in your community for Alzheimer's research.
To discuss ways to become involved and support research at TGen, contact the TGen Foundation at Foundation@tgen.org, or call 602.343.8411.